

# Edward M Sellers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2715163/publications.pdf>

Version: 2024-02-01

227  
papers

16,197  
citations

12330

69  
h-index

18647

119  
g-index

230  
all docs

230  
docs citations

230  
times ranked

9129  
citing authors

#	ARTICLE	IF	CITATIONS
1	5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors as potential targets for the treatment of nicotine use and dependence. <i>Progress in Brain Research</i> , 2021, 259, 229-263.	1.4	3
2	Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. <i>Frontiers in Pharmacology</i> , 2021, 12, 640241.	3.5	31
3	Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 495-504.	2.0	21
4	Identification of Optimal Measures of Human Abuse Potential. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 568-578.	1.4	1
5	Categorization of Abuse Potential-Related Adverse Events. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 569-574.	1.6	2
6	Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 561-564.	4.7	21
7	Studies with psychedelic drugs in human volunteers. <i>Neuropharmacology</i> , 2018, 142, 116-134.	4.1	23
8	Improving the Clinical Pharmacologic Assessment of Abuse Potential. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 113-118.	1.4	2
9	Improving the Clinical Pharmacologic Assessment of Abuse Potential. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 11-18.	1.4	1
10	Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. <i>Epilepsy and Behavior</i> , 2018, 88, 162-171.	1.7	114
11	A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. <i>Journal of Psychopharmacology</i> , 2018, 32, 1351-1361.	4.0	176
12	Opioids: The Painful Public Health Reality. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 924-935.	4.7	5
13	Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 675-683.	1.4	6
14	Deconstructing Designer Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 167-169.	4.7	6
15	Oral Human Abuse Potential of Oxycodone DETERx (Xtampza ER). <i>Journal of Clinical Pharmacology</i> , 2017, 57, 500-512.	2.0	24
16	Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 314-323.	1.4	26
17	Use of Remifentanyl in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent $\mu$ -Receptor Antagonist. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 242-249.	1.4	48
18	Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 396-405.	1.4	43

#	ARTICLE	IF	CITATIONS
19	Claudio A. Naranjo, MD (1945–2014). <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 14-15.	4.7	0
20	Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1161.	2.2	27
21	The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. <i>Pharmaceutical Medicine</i> , 2014, 28, 317-327.	1.9	5
22	Brain Network Activation (BNA) Reveals Scopolamine-Induced Impairment of Visual Working Memory. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 59-70.	2.3	13
23	Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. <i>CNS Drugs</i> , 2014, 28, 361-372.	5.9	15
24	Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 468-477.	2.0	52
25	Human abuse liability evaluation of CNS stimulant drugs. <i>Neuropharmacology</i> , 2014, 87, 81-90.	4.1	25
26	Preventing and managing aberrant drug-related behavior in primary care: Systematic review of outcomes evidence. <i>Journal of Opioid Management</i> , 2014, 10, 119-134.	0.5	21
27	From obesity to substance abuse: therapeutic opportunities for 5-HT <sub>2C</sub> receptor agonists. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 560-570.	8.7	90
28	Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. <i>Journal of Psychopharmacology</i> , 2013, 27, 808-816.	4.0	34
29	A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 285-294.	1.6	28
30	Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. <i>Journal of Pain Research</i> , 2013, 6, 791.	2.0	18
31	Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 492-502.	1.4	13
32	A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2012, 32, e1-e15.	2.2	8
33	Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2012, 32, 157-169.	2.2	17
34	Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. <i>Pain</i> , 2012, 153, 2315-2324.	4.2	49
35	Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria. <i>Clinical Therapeutics</i> , 2012, 34, 1170-1181.	2.5	19
36	Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta <sup>®</sup> , <sup>†</sup> ) tablets in nondependent recreational opioid users. <i>Journal of Opioid Management</i> , 2012, 8, 315-327.	0.5	8

#	ARTICLE	IF	CITATIONS
37	A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2012, 32, e1-e15.	2.2	5
38	A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. <i>Human Psychopharmacology</i> , 2011, 26, 224-236.	1.5	68
39	Effects of Low-Dose Opioids on Cognitive Dysfunction. <i>Journal of Clinical Oncology</i> , 2011, 29, 4342-4343.	1.6	35
40	Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. <i>Journal of Opioid Management</i> , 2011, 7, 179-192.	0.5	25
41	Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release Hydromorphone. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 25-33.	1.4	41
42	Effect of metabolic blockade on the psychoactive effects of dextromethorphan. <i>Human Psychopharmacology</i> , 2010, 25, 71-79.	1.5	23
43	New CYP2A6 gene deletion and conversion variants in a population of Black African descent. <i>Pharmacogenomics</i> , 2010, 11, 189-198.	1.3	31
44	The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. <i>Drug and Alcohol Dependence</i> , 2010, 112, 173-177.	3.2	14
45	Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. <i>Epilepsy and Behavior</i> , 2010, 18, 366-373.	1.7	37
46	Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. <i>Pain Physician</i> , 2010, 13, 561-73.	0.4	8
47	A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. <i>Pharmacogenomics Journal</i> , 2009, 9, 274-282.	2.0	37
48	Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert Panel Report. <i>Drug and Alcohol Dependence</i> , 2009, 105, S65-S71.	3.2	25
49	Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users. <i>Clinical Drug Investigation</i> , 2009, 29, 777-790.	2.2	57
50	Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. <i>Human Mutation</i> , 2008, 29, 679-688.	2.5	69
51	Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1319-1325.	2.6	7
52	Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic. , 2008, , 91-178.		3
53	Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. <i>Carcinogenesis</i> , 2007, 28, 2139-2142.	2.8	35
54	Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1476-1488.	2.0	47

#	ARTICLE	IF	CITATIONS
55	Do Formulation Differences Alter Abuse Liability of Methylphenidate?. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 459-467.	1.4	65
56	Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations. <i>Clinical Journal of Pain</i> , 2007, 23, 648-660.	1.9	138
57	Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. <i>Drug and Alcohol Dependence</i> , 2007, 89, 24-33.	3.2	66
58	The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 604-612.	2.0	18
59	Research design strategies to evaluate the impact of formulations on abuse liability. <i>Drug and Alcohol Dependence</i> , 2006, 83, S52-S62.	3.2	57
60	Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 345-352.	2.0	11
61	Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 481-484.	1.9	21
62	Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. <i>Psychopharmacology</i> , 2006, 186, 425-433.	3.1	111
63	CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1812-1819.	2.5	57
64	Relative abuse potential of opioid formulations in Canada: A structured field study. <i>Journal of Opioid Management</i> , 2006, 2, 219-227.	0.5	16
65	Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1413-1421.	2.0	48
66	Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 189-192.	1.5	37
67	Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 145-158.	4.7	231
68	Nicotine physical dependence and tolerance in the mouse following chronic oral administration. <i>Psychopharmacology</i> , 2005, 178, 183-192.	3.1	79
69	3±-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. <i>Gynecological Endocrinology</i> , 2005, 21, 268-279.	1.7	99
70	Mood changes during pregnancy and the postpartum period: development of a biopsychosocial model. <i>Acta Psychiatrica Scandinavica</i> , 2004, 109, 457-466.	4.5	128
71	EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. <i>Psychopharmacology</i> , 2004, 175, 382-388.	3.1	16
72	Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1132-1142.	2.0	98

#	ARTICLE	IF	CITATIONS
73	Lack of Weight-Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 966-973.	2.0	5
74	Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 615-626.	5.7	279
75	Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. <i>Intensive Care Medicine</i> , 2003, 29, 2230-2238.	8.2	121
76	Measurement issues in postpartum depression part 1: Anxiety as a feature of postpartum depression. <i>Archives of Women's Mental Health</i> , 2003, 6, 51-57.	2.6	238
77	Decreasing smoking behaviour and risk through CYP2A6 inhibition. <i>Drug Discovery Today</i> , 2003, 8, 487-493.	6.4	72
78	Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 437-447.	4.7	129
79	Rat Hepatic CYP2E1 Is Induced by Very Low Nicotine Doses: An Investigation of Induction, Time Course, Dose Response, and Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 941-947.	2.5	42
80	Down-Regulation of Hepatic Nicotine Metabolism and a CYP2A6-Like Enzyme in African Green Monkeys after Long-Term Nicotine Administration. <i>Molecular Pharmacology</i> , 2003, 63, 96-104.	2.3	57
81	The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. <i>Nicotine and Tobacco Research</i> , 2003, 5, 891-899.	2.6	59
82	INTERACTION OF BUPRENORPHINE AND ITS METABOLITE NORBUPRENORPHINE WITH CYTOCHROMES P450 IN VITRO. <i>Drug Metabolism and Disposition</i> , 2003, 31, 768-772.	3.3	51
83	CYP2E1*1D regulatory polymorphism. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 321-328.	5.7	50
84	Title is missing!. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 269-280.	1.4	7
85	Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 269-280.	1.4	25
86	Gender Differences in Tobacco Smoking: Higher Relative Exposure to Smoke Than Nicotine in Women. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2002, 11, 147-153.	1.5	77
87	Metabolism of 18-Methoxycoronaridine, an Ibogaine Analog, to 18-Hydroxycoronaridine by Genetically Variable CYP2C19. <i>Drug Metabolism and Disposition</i> , 2002, 30, 663-669.	3.3	19
88	The role of pharmacogenetically-variable cytochrome P450 enzymes in. <i>Pharmacogenomics</i> , 2002, 3, 185-199.	1.3	53
89	Cortical $\hat{3}$ -Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder. <i>Archives of General Psychiatry</i> , 2002, 59, 851.	12.3	338
90	Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 326-329.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 163-171.	2.0	118
92	Designer Drugs That Are Potent Inhibitors of CYP2D6. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 330-332.	1.4	12
93	Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. <i>Drug Metabolism and Disposition</i> , 2002, 30, 314-318.	3.3	223
94	An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 Alleles. <i>Biochemical and Biophysical Research Communications</i> , 2002, 290, 318-324.	2.1	136
95	CYP2A6 genetic variation and potential consequences. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1245-1256.	13.7	118
96	Reduced (±)-3,4-methylenedioxymethamphetamine (Ecstasy) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , 2002, 63, 2111-2119.	4.4	57
97	Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 192-199.	4.7	33
98	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. <i>Canadian Journal of Physiology and Pharmacology</i> , 2001, 79, 841-847.	1.4	57
99	Use of Hair Analysis for Confirmation of Self-Reported Cocaine Use in Users with Negative Urine Tests. <i>Journal of Toxicology: Clinical Toxicology</i> , 2001, 39, 361-366.	1.5	22
100	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 477-487.	5.7	90
101	Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 85-94.	5.7	47
102	Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain Abbreviations: CYP, cytochrome P450; C8 xanthate, potassium octylxanthate; NCO, nicotine C-oxidation; NDMA, N-nitrosodimethylamine; NMA, N-nitroso-N-methylaniline; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; and SSC, saline-sodium citrate buffer.. <i>Biochemical Pharmacology</i> , 2001, 62, 1025-1036.	4.4	33
103	Cognitive toxicity of drugs used in the elderly. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 181-190.	3.7	8
104	Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 1534-1541.	2.4	5
105	Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 35-43.	4.7	146
106	Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking. <i>Molecular Pharmacology</i> , 2000, 58, 747-755.	2.3	222
107	Lack of Interaction of Buprenorphine With Flunitrazepam Metabolism. <i>American Journal of Psychiatry</i> , 2000, 157, 1164-1166.	7.2	38
108	Mimicking Gene Defects to Treat Drug Dependence. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 233-246.	3.8	40

#	ARTICLE	IF	CITATIONS
109	Long-Term Benzodiazepine Therapy Does Not Result in Brain Abnormalities. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 2-6.	1.4	23
110	Cytochrome P450 2D6 and Treatment of Codeine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 43-45.	1.4	27
111	Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 435-444.	1.4	46
112	Comparative Abuse Liability of Intravenously Administered Remifentanyl and Fentanyl. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 597-606.	1.4	28
113	A Comparative Pharmacokinetic and Dynamic Evaluation of Alprazolam Sustained-Release, Bromazepam, and Lorazepam. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 628-635.	1.4	18
114	Neurosteroids: A New Regulatory Function in the Nervous System. <i>Behavioural Neurology</i> , 1999, 11, 261-262.	2.1	0
115	A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. <i>Nicotine and Tobacco Research</i> , 1999, 1, 63-67.	2.6	31
116	Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 1999, 54, 239-249.	3.2	23
117	Characteristics of Dependent and Nondependent Regular Users of Codeine. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 367-372.	1.4	81
118	Long-Term Codeine Use Is Associated With Depressive Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 373-376.	1.4	45
119	Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 472-475.	1.4	28
120	Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 378-383.	4.7	38
121	Nicotine metabolism defect reduces smoking. <i>Nature</i> , 1998, 393, 750-750.	27.8	359
122	Pharmacogenetics and Ethnoracial Differences in Smoking. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 179.	7.4	57
123	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 305-313.	5.7	82
124	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 325-333.	5.7	85
125	The Extent and Determinants of Changes in CYP2D6 and CYP1A2 Activities With Therapeutic Doses of Sertraline. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 55-61.	1.4	26
126	A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 121-131.	1.4	33



#	ARTICLE	IF	CITATIONS
127	Determinants of Interindividual Variability and Extent of CYP2D6 and CYP1A2 Inhibition by Paroxetine and Fluvoxamine In Vivo. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 198-207.	1.4	24
128	Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 332-337.	1.4	46
129	CYP2D6 phenotype and genotype in a Canadian native indian population. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 145-148.	5.7	20
130	Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 375-379.	5.7	131
131	Interactions of amphetamine analogs with human liver CYP2D6. <i>Biochemical Pharmacology</i> , 1997, 53, 1605-1612.	4.4	153
132	Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1997, 22, 295-304.	1.6	25
133	An improved HPLC method for analysis of methamphetamine and its metabolites in plasma. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1997, 22, 427-432.	1.6	9
134	Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 334-347.	4.7	80
135	CYP2D6 Inhibition in Patients Treated With Sertraline. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 102-106.	1.4	53
136	Multiple Drug Use and Psychiatric Comorbidity in Patients Admitted to the Hospital With Severe Benzodiazepine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 51-57.	1.4	51
137	Effect of the 5-HT <sub>3</sub> antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. <i>Psychopharmacology</i> , 1995, 117, 479-485.	3.1	86
138	Comparative Abuse Liability of Sertraline, Alprazolam, and Dextroamphetamine in Humans. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 117-124.	1.4	38
139	Pharmacokinetics of Dextromethorphan and Metabolites in Humans. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 263-269.	1.4	112
140	Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs. <i>Alcohol Health and Research World</i> , 1995, 19, 34-35.	0.2	0
141	Low doses of the 5-HT <sub>1A</sub> agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake. <i>Psychopharmacology</i> , 1994, 115, 173-179.	3.1	58
142	Influence of 5-HT <sub>3</sub> receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. <i>Psychopharmacology</i> , 1994, 114, 611-619.	3.1	42
143	Effect of dexfenfluramine on saccharin drinking: Behavioural and pharmacological studies. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 47, 307-315.	2.9	5
144	Antagonist-precipitated opioid withdrawal in rats: Evidence for dissociations between physical and motivational signs. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 48, 1-8.	2.9	80

#	ARTICLE	IF	CITATIONS
145	Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 451-463.	4.7	52
146	Clinical Efficacy of the 5-HT <sub>3</sub> Antagonist Ondansetron in Alcohol Abuse and Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 879-885.	2.4	184
147	The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. <i>Brain Research</i> , 1994, 640, 246-254.	2.2	29
148	CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 463-472.	4.7	171
149	Inhibition by fluoxetine of cytochrome P450 2D6 activity. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 401-409.	4.7	252
150	Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , 1993, 45, 963-966.	2.9	17
151	Effect of 5-HT <sub>3</sub> receptor antagonists on the discriminative stimulus properties of morphine in rats. <i>Psychopharmacology</i> , 1993, 112, 111-115.	3.1	24
152	Characteristics of Long-term Alprazolam Users in the Community. <i>Journal of Clinical Psychopharmacology</i> , 1992, 12, 316-321.	1.4	23
153	Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists. <i>Brain Research</i> , 1992, 572, 208-215.	2.2	60
154	The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. <i>Life Sciences</i> , 1992, 50, PL167-PL172.	4.3	70
155	5-HT and alcohol abuse. <i>Trends in Pharmacological Sciences</i> , 1992, 13, 69-75.	8.7	283
156	Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: Studies using a drinkometer system. <i>Neuroscience and Biobehavioral Reviews</i> , 1992, 16, 535-552.	6.1	88
157	Effect of the 5-HT <sub>3</sub> receptor antagonists, MDL72222 and ondansetron on morphine place conditioning. <i>Psychopharmacology</i> , 1992, 106, 315-320.	3.1	85
158	Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide. <i>European Journal of Pharmacology</i> , 1991, 197, 229-230.	3.5	16
159	Characterization of DSM-III-R Criteria for Uncomplicated Alcohol Withdrawal Provides an Empirical Basis for DSM-IV. <i>Archives of General Psychiatry</i> , 1991, 48, 442.	12.3	56
160	Drug metabolism and interactions in abuse liability assessment. <i>Addiction</i> , 1991, 86, 1607-1614.	3.3	7
161	Anxiolytics and sedative/hypnotics dependence. <i>Addiction</i> , 1991, 86, 1647-1652.	3.3	28
162	Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 96-106.	4.7	21

#	ARTICLE	IF	CITATIONS
163	Pharmacotherapy of alcohol and drug problems. <i>Drug and Alcohol Review</i> , 1991, 10, 215-224.	2.1	2
164	Effects of 5-HT <sub>3</sub> receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. <i>Psychopharmacology</i> , 1991, 105, 322-328.	3.1	48
165	Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 490-498.	4.7	226
166	Ethanol interactions with serotonin uptake selective and non-selective antidepressants: Fluoxetine and amitriptyline. <i>Human Psychopharmacology</i> , 1989, 4, 113-120.	1.5	14
167	Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). <i>Addiction</i> , 1989, 84, 1353-1357.	3.3	1,525
168	Differential effects of viqualine on alcohol intake and other consummatory behaviors. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 301-308.	4.7	85
169	Clinical Pharmacokinetics of Non-Opiate Abused Drugs. <i>Clinical Pharmacokinetics</i> , 1989, 16, 1-26.	3.5	94
170	A Clinical Scale to Assess Benzodiazepine Withdrawal. <i>Journal of Clinical Psychopharmacology</i> , 1989, 9, 412-416.	1.4	88
171	Serotonin Uptake Inhibitors Attenuate Ethanol Intake in Humans. <i>Australian Drug and Alcohol Review</i> , 1988, 7, 109-112.	0.1	3
172	A Reply to Dr Andrew Johns. <i>Addiction</i> , 1988, 83, 1116-1117.	3.3	0
173	Defining the true therapeutics and clinical pharmacology curriculum in a canadian medical school: Implications for change. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 629-633.	4.7	8
174	Compliance among heavy alcohol users in clinical drug trials. <i>Journal of Substance Abuse</i> , 1988, 1, 183-194.	1.1	12
175	Drug deprivation and reinforcement by diazepam in a dependent population. <i>Psychopharmacology</i> , 1987, 91, 154-60.	3.1	31
176	The serotonin uptake inhibitor citalopram attenuates ethanol intake. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 266-274.	4.7	237
177	Pharmacokinetic Determinants of Drug Abuse and Dependence. <i>Clinical Pharmacokinetics</i> , 1986, 11, 144-153.	3.5	78
178	Treatment of the barbiturate abstinence syndrome*. <i>Medical Journal of Australia</i> , 1986, 145, 456-458.	1.7	12
179	Patterns of Benzodiazepine Abuse and Dependence. <i>Addiction</i> , 1986, 81, 87-94.	3.3	80
180	Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines. <i>New England Journal of Medicine</i> , 1986, 315, 854-859.	27.0	357

#	ARTICLE	IF	CITATIONS
181	Benzodiazepines as Drugs of Abuse and Dependence. , 1986, , 53-126.		9
182	Clinical Assessment and Pharmacotherapy of the Alcohol Withdrawal Syndrome. Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism, 1986, 4, 265-281.	0.4	43
183	Triazolam and ethanol interaction: Kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics, 1985, 37, 558-562.	4.7	32
184	Acute kinetic and dynamic interactions of zimelidine with ethanol. Clinical Pharmacology and Therapeutics, 1984, 36, 654-660.	4.7	26
185	Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clinical Pharmacology and Therapeutics, 1984, 35, 374-381.	4.7	227
186	Objective Determination of Benzodiazepine Use and Abuse in Alcoholics. Addiction, 1983, 78, 429-435.	3.3	56
187	Nonpharmacologic intervention in acute alcohol withdrawal. Clinical Pharmacology and Therapeutics, 1983, 34, 214-219.	4.7	82
188	IN VITRO QUANTITATION OF BENZODIAZEPINE LIPOPHILICITY: RELATION TO IN VIVO DISTRIBUTION. British Journal of Anaesthesia, 1983, 55, 985-989.	3.4	79
189	Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations. Journal of Clinical Pharmacology, 1982, 22, 259-263.	2.0	115
190	Drug-plasma protein binding in Kutchin Athapaskan Indians. Clinical Pharmacology and Therapeutics, 1982, 32, 436-441.	4.7	2
191	Difficulties in assessing adverse drug reactions in clinical trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1982, 6, 651-657.	4.8	28
192	Age- and sex-related differences in patterns of drug overdose and abuse. Social Science & Medicine Part E, Medical Psychology, 1981, 15, 275-282.	0.2	3
193	Clinical detection and assessment of drug induced neurotoxicity. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1981, 5, 427-434.	0.6	8
194	Development of Optimal Treatment Tactics for Alcohol Withdrawal. I. Assessment and Effectiveness of Supportive Care. Journal of Clinical Psychopharmacology, 1981, 1, 382-389.	1.4	206
195	Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. Clinical Pharmacology and Therapeutics, 1981, 30, 71-76.	4.7	56
196	Phencyclidine Ingestion: Drug Abuse and Psychosis. Substance Use and Misuse, 1981, 16, 749-758.	0.6	11
197	Drugs to Decrease Alcohol Consumption. New England Journal of Medicine, 1981, 305, 1255-1262.	27.0	109
198	The Nature and Etiology of Normal and Alcohol Withdrawal Tremor. IEEE Transactions on Biomedical Engineering, 1979, BME-26, 3-10.	4.2	6

#	ARTICLE	IF	CITATIONS
199	Intravascular factors affecting diazepam binding to human serum albumin. <i>Biochemical Pharmacology</i> , 1979, 28, 3265-3270.	4.4	24
200	Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: A kinetic approach. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 256-264.	4.7	38
201	Chlordiazepoxide and oxazepam disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 240-246.	4.7	52
202	Age- and Gender-Related Differences in Diazepam Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 15-19.	2.0	83
203	Clinical Pharmacokinetics of Chlordiazepoxide. <i>Clinical Pharmacokinetics</i> , 1978, 3, 381-394.	3.5	63
204	Drug Kinetics and Alcohol Ingestion. <i>Clinical Pharmacokinetics</i> , 1978, 3, 440-452.	3.5	97
205	Addictive Drugs: Disposition, Tolerance, and Dependence Interrelationships. <i>Drug Metabolism Reviews</i> , 1978, 8, 5-11.	3.6	16
206	Comparative Metabolism of Chloral Hydrate and Triclofos. <i>Journal of Clinical Pharmacology</i> , 1978, 18, 457-461.	2.0	27
207	The ambiguity of adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 1977, 11, 75-78.	1.9	125
208	Diazepam actions and plasma concentrations following ethanol ingestion. <i>European Journal of Clinical Pharmacology</i> , 1977, 11, 345-349.	1.9	71
209	The effect of propranolol on normal physiologic tremor. <i>Electroencephalography and Clinical Neurophysiology</i> , 1976, 41, 310-313.	0.3	16
210	Binding of Drugs to Serum Albumin. <i>New England Journal of Medicine</i> , 1976, 294, 526-531.	27.0	197
211	Partial Agonist Properties and Toxicity of Oral Oxilorphan. <i>Journal of Clinical Pharmacology</i> , 1976, 16, 183-188.	2.0	2
212	Alcohol Intoxication and Withdrawal. <i>New England Journal of Medicine</i> , 1976, 294, 757-762.	27.0	387
213	Binding of Drugs to Serum Albumin. <i>New England Journal of Medicine</i> , 1976, 294, 311-316.	27.0	379
214	Interaction of warfarin stereoisomers with human albumin. <i>Pharmacological Research Communications</i> , 1975, 7, 331-336.	0.2	42
215	Binding of diazoxide and other benzothiadiazines to human albumin. <i>Biochemical Pharmacology</i> , 1974, 23, 553-566.	4.4	32
216	Clinical pharmacology in Canada. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 554-564.	4.7	0

#	ARTICLE	IF	CITATIONS
217	INFLUENCE OF INTRAVENOUS INJECTION RATE ON PROTEIN BINDING AND VASCULAR ACTIVITY OF DIAZOXIDE. Annals of the New York Academy of Sciences, 1973, 226, 319-332.	3.8	35
218	Survival after massive procainamide ingestion. American Journal of Cardiology, 1973, 32, 727-730.	1.6	29
219	Interaction of chloral hydrate and ethanol in man: I. Metabolism. Clinical Pharmacology and Therapeutics, 1972, 13, 37-49.	4.7	95
220	Interaction of chloral hydrate and ethanol in man: II. Hemodynamics and performance. Clinical Pharmacology and Therapeutics, 1972, 13, 50-58.	4.7	34
221	Drug Interactions with Coumarin Anticoagulants. New England Journal of Medicine, 1971, 285, 487-498.	27.0	247
222	KINETICS AND CLINICAL IMPORTANCE OF DISPLACEMENT OF WARFARIN FROM ALBUMIN BY ACIDIC DRUGS. Annals of the New York Academy of Sciences, 1971, 179, 213-225.	3.8	115
223	Drug Interactions with Coumarin Anticoagulants. New England Journal of Medicine, 1971, 285, 547-558.	27.0	243
224	Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clinical Pharmacology and Therapeutics, 1970, 11, 524-529.	4.7	120
225	Potentiation of Warfarin-Induced Hypoprothrombinemia by Chloral Hydrate. New England Journal of Medicine, 1970, 283, 827-831.	27.0	101
226	Protein Binding and Vascular Activity of Diazoxide. New England Journal of Medicine, 1969, 281, 1141-1145.	27.0	101
227	Modifying the Metabolism of Nicotine as a Therapeutic Strategy. Novartis Foundation Symposium, 0, , 235-248.	1.1	0